Topic
Followed by 1.4k people
TOPIC
The London-based multinational drugmaker, also known as GSK, supplies key products such as vaccines in China, as well as drugs for lung disease and cancer. In 2013, the company was targeted by Chinese authorities over alleged corruption, price-fixing and quality controls.
- Briton says footage broadcast by CCTV via international subsidiary China Global Television Network prejudiced subsequent trial against him
- Humphrey and his wife, Yu Yingzeng, were sentenced in China in 2014 for illegally obtaining and selling Chinese citizens’ private records
After more than three decades in development and almost US$1 billion in investment, the new vaccine began to be distributed in Lilongwe, the nation’s capital.
After more than three decades in development and almost US$1 billion in investment, the new vaccine began to be distributed in Lilongwe, the nation’s capital.
At a closed-door trial held last month in Hunan province, one-time high-flying business executive Mark Reilly was handed a three-year suspended prison sentence for his role in the largest corporate bribery scandal involving a foreign firm in China.
At a closed-door trial held last month in Hunan province, one-time high-flying business executive Mark Reilly was handed a three-year suspended prison sentence for his role in the largest corporate bribery scandal involving a foreign firm in China.
When Cathy Palmer first came to Hong Kong as a US prosecutor more than 20 years ago, she was chasing heroin-smuggling triads who later sent a booby-trapped package to her Brooklyn office.
When Cathy Palmer first came to Hong Kong as a US prosecutor more than 20 years ago, she was chasing heroin-smuggling triads who later sent a booby-trapped package to her Brooklyn office.
In the wake of the Chinese government's punishment of GSK and some of its former senior executives for corruption, multinationals are changing their behaviour and strategies in China, said industry observers.
In the wake of the Chinese government's punishment of GSK and some of its former senior executives for corruption, multinationals are changing their behaviour and strategies in China, said industry observers.
China has imposed a record fine of three billion yuan (HK$3.78 billion) on British pharmaceuticals giant GlaxoSmithKline (GSK) for bribing doctors to use its drugs.
China has imposed a record fine of three billion yuan (HK$3.78 billion) on British pharmaceuticals giant GlaxoSmithKline (GSK) for bribing doctors to use its drugs.
A US anti-bribery probe into GSK touched on the firm's Chinese consumer health care business in 2012, internal documents show, suggesting the drugmaker's compliance problems in China could go wider than previously revealed.
A US anti-bribery probe into GSK touched on the firm's Chinese consumer health care business in 2012, internal documents show, suggesting the drugmaker's compliance problems in China could go wider than previously revealed.
A year after his detention sent shockwaves through China's booming due-diligence industry, British corporate investigator Peter Humphrey admitted in a Shanghai court yesterday that he paid contractors for private information on Chinese citizens for almost a decade.
A year after his detention sent shockwaves through China's booming due-diligence industry, British corporate investigator Peter Humphrey admitted in a Shanghai court yesterday that he paid contractors for private information on Chinese citizens for almost a decade.
The British corporate investigator Peter Humphrey and his Chinese-American wife Yu Yingzeng were handed fines and jail sentences of two years in Shanghai on Friday after being convicted on charges of "illegally obtaining private information".
The British corporate investigator Peter Humphrey and his Chinese-American wife Yu Yingzeng were handed fines and jail sentences of two years in Shanghai on Friday after being convicted on charges of "illegally obtaining private information".
Briton Peter Humphrey and his American wife, Yu Yingzeng, face trial on Friday for illegally obtaining personal information of Chinese citizens.
Briton Peter Humphrey and his American wife, Yu Yingzeng, face trial on Friday for illegally obtaining personal information of Chinese citizens.
The only child of corporate investigators Peter Humphrey and Yu Yingzeng has been allowed to visit his parents in their detention centre in Pudong, Shanghai.
The only child of corporate investigators Peter Humphrey and Yu Yingzeng has been allowed to visit his parents in their detention centre in Pudong, Shanghai.
Corporate sleuth Peter Humphrey believes he worked for the public good by helping victims of crime, according to a letter seen by the Post that he wrote to his son Harvey from prison.
Corporate sleuth Peter Humphrey believes he worked for the public good by helping victims of crime, according to a letter seen by the Post that he wrote to his son Harvey from prison.
The United States has expressed concern after its officials were barred from the Chinese trial of two investigators for British drugmaker GlaxoSmithKline who are accused of illegally buying and selling private information.
The United States has expressed concern after its officials were barred from the Chinese trial of two investigators for British drugmaker GlaxoSmithKline who are accused of illegally buying and selling private information.
British corporate investigator Peter Humphrey and his Chinese-born wife, Yu Yingzeng, will go on trial in Shanghai on July 29.
British corporate investigator Peter Humphrey and his Chinese-born wife, Yu Yingzeng, will go on trial in Shanghai on July 29.
The mainland's crackdown on corruption in the pharmaceutical sector has frightened foreign executives so much that some fear they could be jailed and have asked their lawyers if they should leave the country for six months.
The mainland's crackdown on corruption in the pharmaceutical sector has frightened foreign executives so much that some fear they could be jailed and have asked their lawyers if they should leave the country for six months.
The British Serious Fraud Office has opened formal criminal investigation into the commercial practices of GlaxoSmithKline in "numerous" countries.
The British Serious Fraud Office has opened formal criminal investigation into the commercial practices of GlaxoSmithKline in "numerous" countries.
China's health care reforms present opportunities and challenges to foreign health care firms, according to speakers at a recent hearing of the US-China Economic and Security Review Commission, a United States government agency that advises Congress on Sino-US relations.
China's health care reforms present opportunities and challenges to foreign health care firms, according to speakers at a recent hearing of the US-China Economic and Security Review Commission, a United States government agency that advises Congress on Sino-US relations.
Britain's Serious Fraud Office plans to prosecute or fine some companies for engaging in bribery overseas, and analysts said some cases might involve mainland China, with GlaxoSmithKline and Rolls-Royce as likely targets.
Britain's Serious Fraud Office plans to prosecute or fine some companies for engaging in bribery overseas, and analysts said some cases might involve mainland China, with GlaxoSmithKline and Rolls-Royce as likely targets.
GlaxoSmithKline yesterday reported a drop of £125 million (HK$1.57 billion) in mainland sales last year, prompting the British drug giant to talk up its investments in India without mentioning expansion plans in China.
GlaxoSmithKline yesterday reported a drop of £125 million (HK$1.57 billion) in mainland sales last year, prompting the British drug giant to talk up its investments in India without mentioning expansion plans in China.
GlaxoSmithKline (GSK) said sales on the mainland, where the company faces a bribery probe, have improved since the third quarter, when revenue plunged 61 per cent year on year.
GlaxoSmithKline (GSK) said sales on the mainland, where the company faces a bribery probe, have improved since the third quarter, when revenue plunged 61 per cent year on year.
British drugs maker GlaxoSmithKline will no longer pay doctors to promote its products and will stop tying salaries of sales staff to the number of prescriptions doctors write, its chief executive says, effectively ending two common industry practices that critics have long assailed as conflicts of interest.
British drugs maker GlaxoSmithKline will no longer pay doctors to promote its products and will stop tying salaries of sales staff to the number of prescriptions doctors write, its chief executive says, effectively ending two common industry practices that critics have long assailed as conflicts of interest.
GlaxoSmithKline has decided to spend roughly US$1 billion to raise its stake in its Indian pharmaceutical unit, betting on rising demand in emerging markets as sales in developed economies slow due to a wave of patent expirations.
GlaxoSmithKline has decided to spend roughly US$1 billion to raise its stake in its Indian pharmaceutical unit, betting on rising demand in emerging markets as sales in developed economies slow due to a wave of patent expirations.